PredictImmune announces commercial partnership with Cambridge Clinical Laboratories (CCL) to promote and supply PredictSURE IBDTM, the world´s first validated prognostic test for inflammatory bowel disease
(WorldNews Health)

Partnership with CCL signals PredictImmune´s ever increasing focus on driving sales of PredictSure IBDTM across existing and new markets Cambridge, UK, 21 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with CCL, to provide PredictSURE IBDTM to clinicians and gastroenterologists in the...